Skip to main content
Veterinary Medicines

Neurotranq, solution for injection for dogs and cats

Authorised
  • Acepromazine maleate

Product identification

Medicine name:
Neurotranq, solution for injection for dogs and cats
Неуротранк, инжекционен разтвор за кучета и котки
Active substance:
  • Acepromazine maleate
Target species:
  • Dog
  • Cat
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Acepromazine maleate
    10.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN05AA04
Authorisation status:
  • Valid
Authorised in:
  • Bulgaria
Available in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Alfasan International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Alfasan International B.V.
Responsible authority:
  • Bulgarian Food Safety Authority
Authorisation number:
  • 0022-1420
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 11/12/2023

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 11/12/2023

Labelling

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 11/12/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."